Antibiotics Market Size

Your Catalyst To a Lucrative Business
Antibiotics Market Share, Size, Analysis, Growth, Trends and
Forecasts to 2022 | Hexa Research
" The global antibiotics market is expected to foresee
significant growth over the forecast period."
The global Antibiotics Market is expected to foresee significant growth over the forecast period. An antibiotic is
a type of antimicrobial used to treat a number of bacterial infections and to slow down the growth of such
infections in the body. The global market for antibiotics is witnessing immense growth due to rising investments
in research and development activities along with continuous product innovations by major companies. Rising
awareness regarding the advantages of antibiotics, particularly in Asia Pacific, is also likely to drive the market.
Companies that accounted for most of this increase were based in regions including China, Braz il, India, Russia,
and South Africa.
Product consumption varies significantly in different countries as per demand. Two classes of antibiotic drugs
including carbapenems and polymyxins have shown increase in the consumption in past few years and this
trend is expected to continue even during the forecast period. Over the past few years, numerous companies
have been engaged in product manufacturing and about 79% of the global demand is covered by
aminoglycoside. There are various products present in the market such as tetracyclines, penicillin,
erythromycin, chloramphenicol, and streptomycin. Factors such as rising demand for effective drugs and
increasing prevalence of infectious diseases, especially in emerging economies including Middle East, Africa,
Latin America, and Asia Pacific, are significant growth drivers for the market.
Browse Details of Report @
Follow Us:
Your Catalyst To a Lucrative Business
This trend is expected to continue over the next few years. Rising geriatric population is also anticipated to
contribute toward the market expansion in the years to come. The main challenge this industry is facing is
emergence of drug resistant strains. As in the category of drugs, antibacterial drugs have various unique
characteristics, which make them little less profitable and therefore less attractive investments. These drugs
are prescribed for short course of time, anywhere from 4 days to 2 weeks as compared to the medications for
cholesterol and anti-hypertensive patients, which last for several years or decades. Innovation in technical
development is the key opportunity for the market. Numerous companies in this field are continually investing
to develop new, advanced products in order to increase their product portfolio.
Major attention is focused on research and development of vital but less profitable antibacterial drug for the
companies to sell at a premium price. The demand for antibiotics is rising particularly to treat children with
pneumonia and sepsis. In most countries, 20% of the product is used by healthcare facilities and hospitals while
80% is used by the community. These are either purchased directly by the consumers or are prescribed by the
healthcare providers.
Antibiotics can be classified into seven major classes namely phenicols, quinolones, macrolides, sulfonamides,
aminoglycosides, tetracyclines, and beta lactams. Around half of the market share was claimed by beta lactams
class in the past. The second largest class was quinolones. However, the market will experience a decline as a
result of the adverse effects on sales due to patent expiries. However, fluoroquinolones/quinolones is expected
to foresee a significant demand in the market over the forecast period as they are used in treating a large
number of infections.
Some of the key companies operating in the global market are Pfizer, Inc.; Abbott Laboratori es;
GlaxoSmithKline PLC; Daiichii Sankyo Company Limited; Bayer HealthCare Pharmaceuticals LLC; Astellas
Pharma, Inc.; Merck & Company, Inc.; Roche Holding AG; Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc.;
GlaxoSmithKline Plc; Pliva d.dd; Toyama Chemica Co. Ltd.; Takeda Pharmaceutical Company. Ltd.; Johnson &
Johnson; LG Life Sciences Limited; and Eli Lilly and Co. Pfizer Inc. contributed to the largest share in the past,
followed by GlaxoSmithKline PLC and Merck & Company, Inc. With very few patented products available at
present, generic manufacturers are leading the global market for antibiotics.
Browse Related Category Market Reports @
Follow Us:
Your Catalyst To a Lucrative Business
About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research
and consulting services to a host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients obtain clarity about their business
environment and enable them to undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: [email protected]
Website -
Follow Us:

The global market for antibiotics is witnessing immense growth due to rising investments in research and development activities.